World J Clin Oncol. 2014 Dec 10;5(5):1078-87. doi: 10.5306/wjco.v5.i5.1078.

Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer.

World journal of clinical oncology

Saleh A Almatroodi, Christine F McDonald, Allison L Collins, Ian A Darby, Dodie S Pouniotis

PMID: 25493244 PMCID: PMC4259935 DOI: 10.5306/wjco.v5.i5.1078

Abstract

AIM: To evaluate the M1 and M2 monocyte phenotype in patients with non-small cell lung cancer (NSCLC) compared to controls. Also, to examine the expression of Th1 and Th2 cytokines in plasma of NSCLC vs controls.

METHODS: Freshly prepared peripheral blood mononuclear cells samples were obtained from patients with NSCLC (lung adenocarcinoma and squamous cell lung carcinoma) and from non-cancer controls. Flow cytometry was performed to investigate M1 and M2 phenotypes in peripheral monocytes (classical monocytes CD14+, CD45+ and CD16-) using conventional surface markers. Th1 and Th2 cytokine production was also analysed in the plasma using cytometric bead array technique.

RESULTS: There were no significant difference in expression of M1 (HLA-DR) and/or M2 markers (CD163 and CD36) markers on classical monocytes in patients with NSCLC compared to non-cancer controls. Expression of CD11b, CD11c, CD71 and CD44 was also shown to be similar in patients with NSCLC compared to non-cancer controls. Th1 and Th2 cytokines [interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12 (p70), tumor necrosis factor (TNF)-α, TNF-β, and interferon-γ] analysis revealed no significant difference between patients with NSCLC and non-cancer controls.

CONCLUSION: This study shows no alteration in peripheral monocyte phenotype in circulating classical monocytes in patients with NSCLC compared to non-cancer controls. No difference in Th1 and Th2 cytokine levels were noted in the plasma of these patients.

Keywords: Lung cancer; Monocyte; Phenotype; Polarisation; Tumour progression; Tumour regression

References

1. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H656-63 - PubMed
2. Nat Immunol. 2002 Nov;3(11):991-8 - PubMed
3. Clin Cancer Res. 1999 Apr;5(4):933-6 - PubMed
4. J Clin Immunol. 1995 May;15(3):121-9 - PubMed
5. J Surg Res. 2004 Feb;116(2):277-87 - PubMed
6. J Immunol. 2008 Apr 15;180(8):5257-66 - PubMed
7. Biochim Biophys Acta. 2013 Apr;1835(2):170-9 - PubMed
8. Genome Biol. 2005;6(2):R15 - PubMed
9. Eur J Radiol. 2003 Jan;45(1):8-17 - PubMed
10. Rev Diabet Stud. 2007 Summer;4(2):112-7 - PubMed
11. Cancer Res. 2010 Jul 15;70(14):5728-39 - PubMed
12. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8363-8 - PubMed
13. Cancer Res. 1994 Jan 15;54(2):422-6 - PubMed
14. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 1):225-35 - PubMed
15. Diabetes Care. 2010 Jan;33(1):e7 - PubMed
16. Tuber Lung Dis. 1995 Aug;76(4):370-1 - PubMed
17. J Transl Med. 2011 Jun 09;9:90 - PubMed
18. Breast Cancer Res Treat. 2010 Jan;119(2):283-93 - PubMed
19. Int J Gynecol Cancer. 2012 Nov;22(9):1500-8 - PubMed
20. PLoS One. 2012;7(7):e40677 - PubMed
21. Prostate. 2010 Mar 1;70(4):443-55 - PubMed
22. Blood. 1996 Mar 1;87(5):2020-8 - PubMed
23. Clin Vaccine Immunol. 2006 Jun;13(6):704-7 - PubMed
24. Lung Cancer. 1997 Oct;18(2):147-57 - PubMed
25. Radiographics. 2010 Sep;30(5):1163-81 - PubMed
26. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
27. Biochem Biophys Res Commun. 2012 Jun 29;423(2):331-7 - PubMed
28. Jpn J Cancer Res. 1996 Nov;87(11):1191-4 - PubMed
29. Cancer. 1995 Jul 1;76(1):20-5 - PubMed
30. Anticancer Res. 2008 Jan-Feb;28(1A):187-92 - PubMed
31. Cell. 2010 Apr 2;141(1):39-51 - PubMed
32. Br J Cancer. 1997;75(12):1802-6 - PubMed
33. Eur Rev Med Pharmacol Sci. 2002 Jul-Aug;6(4):67-73 - PubMed

Publication Types

• Journal Article